All News

Heel, pain,enthesitis,achilles

MSK Symptoms from Dupilimab, an IL-4/13 Inhibitor

Jack Cush, MD

A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab.

Read Article
psA.fil_.Hands_.jpg

Brepocitinib in Active Psoriatic Arthritis

Jack Cush, MD

Brepocitinib is a novel tyrosine kinase 2/Janus kinase 1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks.

Read Article
PSA068.jpg

Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis

Jack Cush, MD

Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients.

Read Article
RheumNow Podcast square

One in Ten is Bad! (5.12.2023)

Jack Cush, MD

This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!

Read Article
brain headache neuro

Treatment and Management of Neuropsychiatric Lupus

Eric Dein, MD

On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder. 

Read Article
pneumocystis,PJP

PJP Prophylaxis Needed with Steroids and Rituximab

Jack Cush, MD

Pneumocystis jirovecii pneumonia (PJP) can be a life-threatening infection in immunocompromised patients. The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving rituximab (RTX).

Read Article
RheumNow Podcast square

National Population Insights (4.28.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.

Read Article
RheumNow Podcast square

Want to Go Far, Go Together (4.21.2023)

Jack Cush, MD

This week on the podcast Dr. Jack Cush reviews the news, regulatory announcements and novel journal reports including a profile on pseudogout, the safety of immune checkpoint inhibitors in RA patients and the diagnostic importance of neutrophils.

Read Article
Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis Analysis of patient data from five Nordic registries shows that the uptake of newer b/tsDMARDs in PsA was mainly in biologic-experienced patients. https://t.co/SP9ZKGvM0J https://t.co/1tfSiWHYfl

Links:

Dr. John Cush RheumNow ( View Tweet)

Orphan drugs target rare dz <200k. New drugs (2008-2016) compared 5 yr sales 86 orphan Rx to 232 non-orphan = similar sales- Orphan ($719 mill) vs nonorphan ($812 mill). But orphan Rx lower volume offset by higher prices (7X higher) than nonorphan drugs https://t.co/I8kb4A0eyG https://t.co/gEQpssRVkg

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/0mC7PxF0DU https://t.co/klbnwjcPbM

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023 @RheumNow There are a lot of RA Rx on market now - do we need more? Dr. Brenner: YES Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/Og1vvbTRO9 https://t.co/WyqPH0lgkd

Links:

Dr. John Cush RheumNow ( View Tweet)
PJP Prophylaxis Needed with Steroids and RTX The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving RTX. https://t.co/eq42bK7MB1 https://t.co/Wk1hOpXanv

Links:

Dr. John Cush RheumNow ( View Tweet)
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/wfrlAcij8x https://t.co/OvqKrHw5Wu

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us 4/25 as we conclude our Women in Rheumatology campaign by focusing on what's next. Our panelists will recap the challenges addressed this month and discuss a strategy to suppot women in rheumatology. https://t.co/DP4S2hf5Tz @uptoTate @KDAO2011 @gwenesta_melton https://t.co/rcglaZxqoF

Links:

Dr. John Cush RheumNow ( View Tweet)
TNR: Private Practice & Academia In this session, our panelists addressed the big questions of: "How do I choose between private practice and academia?" and "How do I advance in my career?". https://t.co/yMJ5mCtSXX @KDAO2011 https://t.co/eeFYkLYsAh

Links:

Dr. John Cush RheumNow ( View Tweet)
Real world interchangeabilty study compared rituximab to biosimilar ( CT-P10) in 128 Rheum pts (CT-P10= 64; RTX= 64), with 41% of pts switched from RTX to CT-P10. Both Rx had Comparable Gr 2 infuxion Rxs, infection #s & hypogammaglobulinemia (p > 0.05) https://t.co/RNxt7Xn7MJ https://t.co/u3yJNQQIMC

Links:

Dr. John Cush RheumNow ( View Tweet)
Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis A retrospective study of cancer patients who developed ICI-IA shows that biologic DMARDs were more effective than csDMARDs in rapid control of arthritis. https://t.co/EQjSgav0by https://t.co/CZ0IqR3UXM

Links:

Dr. John Cush RheumNow ( View Tweet)
RA Patients on Biologics and tsDMARDs are still High Risk A new Swedish ARTIS registry study of key safety outcomes in RA patients receiving either targeted synthetic or b/ts DMARDs, including JAKi, has been updated and affirms previously held risks. https://t.co/mqfP4deGJv https://t.co/m43GSRlrct

Links:

Dr. John Cush RheumNow ( View Tweet)
Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis A retrospective study of cancer patients who developed ICI-IA shows that biologic DMARDs were more effective than csDMARDs in rapid control of arthritis. https://t.co/O5bMpwwM8Z https://t.co/H27RSA3oMt

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×